Advanced search
Publication Cover
OncoTargets and Therapy Volume 17, 2024 - Issue
Submit an article Journal homepage
115
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Clinical Response of Advanced Lung Adenocarcinoma with Class III BRAF G466V Missense Mutation to Dabrafenib and Trametinib: A Case Report

Ruoxin FangDepartment of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Wuhan, Hubei, 430071, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-5395-3583
ORCID Icon,
Sha XuDepartment of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Wuhan, Hubei, 430071, People’s Republic of China
,
Jun GongDepartment of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Wuhan, Hubei, 430071, People’s Republic of China
&
Zhengkai LiaoDepartment of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Wuhan, Hubei, 430071, People’s Republic of ChinaCorrespondence[email protected]
Pages 27-31 | Received 16 Nov 2023, Accepted 11 Jan 2024, Published online: 23 Jan 2024

References

  • Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of American pathologists, the international association for the study of lung cancer, and the association for molecular pathology. J Thorac Oncol. 2018;13(3):323–358. doi:10.1016/j.jtho.2017.12.001
  • Sheikine Y, Pavlick D, Klempner SJ, et al. BRAF in lung cancers: analysis of patient cases reveals recurrent BRAF Mutations, fusions, kinase duplications, and concurrent alterations. JCO Precis Oncol. 2018;2:PO.17.00172. doi:10.1200/po.17.00172
  • Fiskus W, Mitsiades N. B-raf inhibition in the clinic: present and future. Annu Rev Med. 2016;67(1):29–43. doi:10.1146/annurev-med-090514-030732
  • Fedorenko IV, Paraiso KH, Smalley KS. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol. 2011;82(3):201–209. doi:10.1016/j.bcp.2011.05.015
  • Nguyen-Ngoc T, Bouchaab H, Adjei AA, Peters S. BRAF alterations as therapeutic targets in non-small-cell lung cancer. J Thorac Oncol. 2015;10(10):1396–1403. doi:10.1097/jto.0000000000000644
  • Planchard D, Kim TM, Mazieres J, et al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, Phase 2 trial. Lancet Oncol. 2016;17(5):642–650. doi:10.1016/s1470-2045(16)00077-2
  • Menzer C, Menzies AM, Carlino MS, et al. Targeted therapy in advanced melanoma with rare BRAF mutations. J Clin Oncol. 2019;37(33):3142–3151. doi:10.1200/jco.19.00489
  • Yao Z, Yaeger R, Rodrik-Outmezguine VS, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 2017;548(7666):234–238. doi:10.1038/nature23291
  • Sakai T, Matsumoto S, Ueda Y, et al. Clinico-genomic features and targetable mutations in non-small cell lung cancers harboring BRAF non-V600E mutations: a multi-institutional genomic screening study (LC-SCRUM-Asia). J Thorac Oncol. 2023;18(11):1538–1549. doi:10.1016/j.jtho.2023.07.024
  • Fontana E, Valeri N. Class(y) dissection of BRAF heterogeneity: beyond non-V600. Clin Cancer Res. 2019;25(23):6896–6898. doi:10.1158/1078-0432.Ccr-19-2732
  • Riley DS, Barber MS, Kienle GS, et al. CARE guidelines for case reports: explanation and elaboration document. J Clin Epidemiol. 2017;89:218–235. doi:10.1016/j.jclinepi.2017.04.026
  • Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The Eighth edition lung cancer stage classification. Chest. 2017;151(1):193–203. doi:10.1016/j.chest.2016.10.010
  • Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
  • Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29(15):2046–2051. doi:10.1200/jco.2010.33.1280
  • Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307–1316. doi:10.1016/s1470-2045(17)30679-4
  • Mazieres J, Cropet C, Montané L, et al. Vemurafenib in non-small-cell lung cancer patients with BRAF(V600) and BRAF(nonV600) mutations. Ann Oncol. 2020;31(2):289–294. doi:10.1016/j.annonc.2019.10.022
  • Johnson DB, Zhao F, Noel M, et al. Trametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: results from NCI-MATCH (EAY131). Clin Cancer Res. 2020;26(8):1812–1819. doi:10.1158/1078-0432.Ccr-19-3443
  • Noeparast A, Teugels E, Giron P, et al. Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib. Oncotarget. 2017;8(36):60094–60108. doi:10.18632/oncotarget.11635
  • Dankner M, Wang Y, Fazelzad R, et al. Clinical activity of mitogen-activated protein kinase-targeted therapies in patients with non-V600 BRAF-mutant tumors. JCO Precis Oncol. 2022;6(6):e2200107. doi:10.1200/po.22.00107
  • Lito P, Saborowski A, Yue J, et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell. 2014;25(5):697–710. doi:10.1016/j.ccr.2014.03.011
  • King AJ, Arnone MR, Bleam MR, et al. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS One. 2013;8(7):e67583. doi:10.1371/journal.pone.0067583
  • Rustgi N, Maria A, Toumbacaris N, et al. Combined RAF and MEK inhibition to treat activated non-V600 BRAF-altered advanced cancers. Oncologist. 2023;24:oyad247. doi:10.1093/oncolo/oyad247

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.